Bayer Study On Parkinson's Disease Gene Therapy Succeeds In Early-Stage Trial

Zinger Key Points
  • No serious adverse events have been attributed to Bayer's AB-1005, with clinical follow-up for up to five years post-administration ongoing.
  • Gene therapy AB-1005 was well tolerated in mild to moderate Parkinson’s disease patients.

Bayer AG BAYRY BAYZF and Asklepios BioPharmaceutical Inc completed an 18-month data collection in the Phase Ib trial for AB-1005 (AAV2-GDNF), an investigational gene therapy for treating patients with Parkinson's disease (PD).

The study met its primary objective, which was to evaluate the safety of a one-time bilateral delivery of AB-1005 directly to the putamen. 

Eleven patients were enrolled into two cohorts, Mild stage PD (six patients) and Moderate stage PD (5 patients), based upon the timing from a PD diagnosis and the severity of their PD symptoms at screening.

Neurosurgical delivery of AB-1005 was well tolerated by all patients with target putamen coverage of 63% ± 2%, exceeding the goal of greater than 50% coverage with AB-1005. 

Also ReadLegal Victory For Bayer – Roundup Lawsuit Ends Five-Trial Losing Streak.

No serious adverse events have been attributed to AB-1005, with continued clinical follow-up for up to 5 years post-administration ongoing.

Krystof Bankiewicz, Scientific Chair, Parkinson's and MSA at AskBio is “encouraged by these early data.”

AskBio is planning to present the 18-month study data, including secondary endpoints, at a scientific meeting in Q2 2024. Planning is currently underway for a Phase 2 trial.

The study is expected to begin screening patients soon.

In November, Bayer stopped the OCEANIC-AF Phase 3 study investigating asundexian compared to apixaban (a direct oral anticoagulant) in patients with atrial fibrillation at risk for stroke.

Now Read: Alibaba Vs. PDD: Shifting Market Dynamics Of China’s E-Commerce Landscape

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareTop StoriesGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!